Cargando…

Electrostatic Interactions Explain the Higher Binding Affinity of the CR3022 Antibody for SARS-CoV-2 than the 4A8 Antibody

[Image: see text] A structural understanding of the mechanism by which antibodies bind SARS-CoV-2 at the atomic level is highly desirable as it can tell the development of more effective antibodies to treat Covid-19. Here, we use steered molecular dynamics (SMD) and coarse-grained simulations to est...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Hung, Lan, Pham Dang, Nissley, Daniel A., O’Brien, Edward P., Li, Mai Suan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276604/
https://www.ncbi.nlm.nih.gov/pubmed/34228472
http://dx.doi.org/10.1021/acs.jpcb.1c03639
_version_ 1783721933879115776
author Nguyen, Hung
Lan, Pham Dang
Nissley, Daniel A.
O’Brien, Edward P.
Li, Mai Suan
author_facet Nguyen, Hung
Lan, Pham Dang
Nissley, Daniel A.
O’Brien, Edward P.
Li, Mai Suan
author_sort Nguyen, Hung
collection PubMed
description [Image: see text] A structural understanding of the mechanism by which antibodies bind SARS-CoV-2 at the atomic level is highly desirable as it can tell the development of more effective antibodies to treat Covid-19. Here, we use steered molecular dynamics (SMD) and coarse-grained simulations to estimate the binding affinity of the monoclonal antibodies CR3022 and 4A8 to the SARS-CoV-2 receptor-binding domain (RBD) and SARS-CoV-2 N-terminal domain (NTD). Consistent with experiments, our SMD and coarse-grained simulations both indicate that CR3022 has a higher affinity for SARS-CoV-2 RBD than 4A8 for the NTD, and the coarse-grained simulations indicate the former binds three times stronger to its respective epitope. This finding shows that CR3022 is a candidate for Covid-19 therapy and is likely a better choice than 4A8. Energetic decomposition of the interaction energies between these two complexes reveals that electrostatic interactions explain the difference in the observed binding affinity between the two complexes. This result could lead to a new approach for developing anti-Covid-19 antibodies in which good candidates must contain charged amino acids in the area of contact with the virus.
format Online
Article
Text
id pubmed-8276604
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-82766042021-07-13 Electrostatic Interactions Explain the Higher Binding Affinity of the CR3022 Antibody for SARS-CoV-2 than the 4A8 Antibody Nguyen, Hung Lan, Pham Dang Nissley, Daniel A. O’Brien, Edward P. Li, Mai Suan J Phys Chem B [Image: see text] A structural understanding of the mechanism by which antibodies bind SARS-CoV-2 at the atomic level is highly desirable as it can tell the development of more effective antibodies to treat Covid-19. Here, we use steered molecular dynamics (SMD) and coarse-grained simulations to estimate the binding affinity of the monoclonal antibodies CR3022 and 4A8 to the SARS-CoV-2 receptor-binding domain (RBD) and SARS-CoV-2 N-terminal domain (NTD). Consistent with experiments, our SMD and coarse-grained simulations both indicate that CR3022 has a higher affinity for SARS-CoV-2 RBD than 4A8 for the NTD, and the coarse-grained simulations indicate the former binds three times stronger to its respective epitope. This finding shows that CR3022 is a candidate for Covid-19 therapy and is likely a better choice than 4A8. Energetic decomposition of the interaction energies between these two complexes reveals that electrostatic interactions explain the difference in the observed binding affinity between the two complexes. This result could lead to a new approach for developing anti-Covid-19 antibodies in which good candidates must contain charged amino acids in the area of contact with the virus. American Chemical Society 2021-07-06 2021-07-15 /pmc/articles/PMC8276604/ /pubmed/34228472 http://dx.doi.org/10.1021/acs.jpcb.1c03639 Text en © 2021 The Authors. Published by American Chemical Society Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Nguyen, Hung
Lan, Pham Dang
Nissley, Daniel A.
O’Brien, Edward P.
Li, Mai Suan
Electrostatic Interactions Explain the Higher Binding Affinity of the CR3022 Antibody for SARS-CoV-2 than the 4A8 Antibody
title Electrostatic Interactions Explain the Higher Binding Affinity of the CR3022 Antibody for SARS-CoV-2 than the 4A8 Antibody
title_full Electrostatic Interactions Explain the Higher Binding Affinity of the CR3022 Antibody for SARS-CoV-2 than the 4A8 Antibody
title_fullStr Electrostatic Interactions Explain the Higher Binding Affinity of the CR3022 Antibody for SARS-CoV-2 than the 4A8 Antibody
title_full_unstemmed Electrostatic Interactions Explain the Higher Binding Affinity of the CR3022 Antibody for SARS-CoV-2 than the 4A8 Antibody
title_short Electrostatic Interactions Explain the Higher Binding Affinity of the CR3022 Antibody for SARS-CoV-2 than the 4A8 Antibody
title_sort electrostatic interactions explain the higher binding affinity of the cr3022 antibody for sars-cov-2 than the 4a8 antibody
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276604/
https://www.ncbi.nlm.nih.gov/pubmed/34228472
http://dx.doi.org/10.1021/acs.jpcb.1c03639
work_keys_str_mv AT nguyenhung electrostaticinteractionsexplainthehigherbindingaffinityofthecr3022antibodyforsarscov2thanthe4a8antibody
AT lanphamdang electrostaticinteractionsexplainthehigherbindingaffinityofthecr3022antibodyforsarscov2thanthe4a8antibody
AT nissleydaniela electrostaticinteractionsexplainthehigherbindingaffinityofthecr3022antibodyforsarscov2thanthe4a8antibody
AT obrienedwardp electrostaticinteractionsexplainthehigherbindingaffinityofthecr3022antibodyforsarscov2thanthe4a8antibody
AT limaisuan electrostaticinteractionsexplainthehigherbindingaffinityofthecr3022antibodyforsarscov2thanthe4a8antibody